HP

Across TCGA pan-cancer cohorts, HP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HP data layer compared with 26 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher HP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HP expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THCA, LIHC, and UCEC are the cancer types where HP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.255	0.954	<.001	20	view →
LIHC	DFS	Median	All	0.094	0.526	.017	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.136	0.758	.002	6	view →
SKCM	DFS	Median	III,IV	1.000	0.247	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HP–THCA (OS)

Open the THCA breakdown →